Dynavax Technologies Corp
DVAX11.080USD
+0.220+2.03%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
1.37BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Dynavax Technologies Corp Unternehmen
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Unternehmensinformationen
BörsenkürzelDVAX
Name des UnternehmensDynavax Technologies Corp
IPO-datumFeb 19, 2004
CEOMr. Ryan Spencer
Anzahl der mitarbeiter405
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 19
Addresse2100 Powell Street
StadtEMERYVILLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94608
Telefon15108485100
Websitehttps://www.dynavax.com/
BörsenkürzelDVAX
IPO-datumFeb 19, 2004
CEOMr. Ryan Spencer
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
277.67K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. David F. Novack
Mr. David F. Novack
President, Chief Operating Officer
President, Chief Operating Officer
56.05K
+33.36%
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
31.42K
--
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+23.89%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
25.52K
--
Dr. Peter R. Paradiso, Ph.D.
Dr. Peter R. Paradiso, Ph.D.
Independent Director
Independent Director
24.83K
+30.19%
Dr. Daniel L. (Dan) Kisner, M.D.
Dr. Daniel L. (Dan) Kisner, M.D.
Independent Director
Independent Director
23.33K
+32.77%
Mr. Brent MacGregor
Mr. Brent MacGregor
Independent Director
Independent Director
21.83K
+35.83%
Dr. Emilio Emini
Dr. Emilio Emini
Independent Director
Independent Director
1.44K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Ryan Spencer
Mr. Ryan Spencer
Chief Executive Officer, Director
Chief Executive Officer, Director
277.67K
--
Dr. Robert (Rob) Janssen, M.D.
Dr. Robert (Rob) Janssen, M.D.
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
Chief Medical Officer, Senior Vice President - Clinical Development, Medical and Regulatory Affairs
74.92K
--
Mr. David F. Novack
Mr. David F. Novack
President, Chief Operating Officer
President, Chief Operating Officer
56.05K
+33.36%
Mr. John L. Slebir
Mr. John L. Slebir
Senior Vice President, General Counsel
Senior Vice President, General Counsel
31.42K
--
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
29.86K
+23.89%
Ms. Kelly MacDonald, CPA
Ms. Kelly MacDonald, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
25.52K
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
HEPLISAV-B
64.96M
95.30%
Other revenue
3.21M
4.70%
Nach RegionUSD
Name
Umsatz
Anteil
US
67.81M
99.47%
Non-US
358.00K
0.53%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
HEPLISAV-B
64.96M
95.30%
Other revenue
3.21M
4.70%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
15.53%
Deep Track Capital LP
14.82%
The Vanguard Group, Inc.
7.22%
State Street Global Advisors (US)
5.65%
Tang Capital Management, LLC
4.79%
Other
51.99%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
15.53%
Deep Track Capital LP
14.82%
The Vanguard Group, Inc.
7.22%
State Street Global Advisors (US)
5.65%
Tang Capital Management, LLC
4.79%
Other
51.99%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
40.52%
Hedge Fund
38.07%
Investment Advisor/Hedge Fund
21.73%
Research Firm
5.56%
Pension Fund
1.34%
Individual Investor
0.59%
Sovereign Wealth Fund
0.57%
Bank and Trust
0.55%
Venture Capital
0.06%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
551
130.99M
109.09%
-16.02M
2025Q1
575
132.57M
110.30%
-15.70M
2024Q4
565
133.92M
107.04%
-18.98M
2024Q3
561
132.88M
101.45%
-18.82M
2024Q2
547
135.21M
103.33%
-14.69M
2024Q1
545
136.49M
104.51%
-4.07M
2023Q4
529
128.50M
99.42%
-9.47M
2023Q3
515
128.65M
99.89%
-9.14M
2023Q2
503
129.32M
100.65%
-12.27M
2023Q1
497
129.65M
101.54%
-1.28M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
18.65M
15.53%
-799.41K
-4.11%
Mar 31, 2025
Deep Track Capital LP
17.79M
14.82%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
8.67M
7.22%
-459.90K
-5.04%
Mar 31, 2025
State Street Global Advisors (US)
6.79M
5.65%
-1.00M
-12.88%
Mar 31, 2025
Tang Capital Management, LLC
5.75M
4.79%
+3.90M
+210.81%
Mar 31, 2025
Chicago Capital, LLC
5.34M
4.45%
-36.81K
-0.68%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
4.32%
-2.33K
-0.04%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
4.01M
3.34%
-58.27K
-1.43%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.07M
2.55%
+71.47K
+2.39%
Mar 31, 2025
Renaissance Technologies LLC
2.71M
2.25%
+350.25K
+14.87%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco Biotechnology & Genome ETF
2.7%
Virtus LifeSci Biotech Products ETF
1.84%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.15%
ETC 6 Meridian Small Cap Equity ETF
0.79%
Invesco S&P SmallCap Health Care ETF
0.79%
Franklin Genomic Advancements ETF
0.64%
Themes US Small Cap Cash Flow Champions ETF
0.45%
SPDR S&P Biotech ETF
0.41%
Royce Quant Small-Cap Quality Value ETF
0.32%
ETC 6 Meridian Low Beta Equity Strategy ETF
0.29%
Mehr Anzeigen
Invesco Biotechnology & Genome ETF
Anteil2.7%
Virtus LifeSci Biotech Products ETF
Anteil1.84%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Anteil1.15%
ETC 6 Meridian Small Cap Equity ETF
Anteil0.79%
Invesco S&P SmallCap Health Care ETF
Anteil0.79%
Franklin Genomic Advancements ETF
Anteil0.64%
Themes US Small Cap Cash Flow Champions ETF
Anteil0.45%
SPDR S&P Biotech ETF
Anteil0.41%
Royce Quant Small-Cap Quality Value ETF
Anteil0.32%
ETC 6 Meridian Low Beta Equity Strategy ETF
Anteil0.29%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
